A Mass Balance Study of [14C]ABSK011

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

November 7, 2025

Study Completion Date

April 7, 2026

Conditions
Healthy Subjects
Interventions
DRUG

[14C]ABSK011

The standard meal was taken the night before administration, and the patient was fasted for at least 10 h without drinking water overnight. The next morning, eat a low-fat meal, finish the meal within 30 minutes, and take the test drug with warm water 30 minutes (±5 minutes) after the beginning of the meal. The total volume of warm water and suspension liquid is about 240 mL. Except for meals and administration, no water was allowed 1 hour before and 1 hour after medication. No food is allowed for 4 hours after taking the medication. Throughout the study, participants received meals provided by the center at approximately the same time each day.

Trial Locations (1)

102206

Beijing GoBroad Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY

NCT06896760 - A Mass Balance Study of [14C]ABSK011 | Biotech Hunter | Biotech Hunter